GILVOCARCINS, NEW ANTI-TUMOR ANTIBIOTICS .3. ANTI-TUMOR ACTIVITY
GILVOCARCINS, NEW ANTI-TUMOR ANTIBIOTICS .3. ANTI-TUMOR ACTIVITY
复制标题
DOI：
10.7164/antibiotics.34.701
复制
发表时间：
1981-01-01
影响因子：
3.3
通讯作者：
MARUMO, H
中科院分区：
文献类型：
--
作者：
MORIMOTO, M;OKUBO, S;MARUMO, H
从链霉菌培养物中分离的Gilvocarcin V显示出抗实验肿瘤如肉瘤180、埃利希癌、Meth1纤维肉瘤、MH 134肝细胞瘤和淋巴细胞白血病P388的活性。在经处理的小鼠中，在对携带埃利希腹水癌的小鼠腹膜内给予gilvocarcin V后，40%的小鼠存活60天。但它对B16黑色素瘤的活性很低，并且不能延长携带刘易斯肺癌的小鼠的寿命。
Gilvocarcin V, isolated from a Streptomyces culture, showed activity against experimental tumors such as sarcoma 180, Ehrlich carcinoma, Meth 1 fibrosarcoma, MH134 hepatoma and lymphocytic leukemia P388. Of the treated mice, 40% survived for 60 days after i.p. administration of gilvocarcin V to mice bearing Ehrlich ascites carcinoma. But it was marginally active against B16 melanoma and did not prolong the lifespan of mice bearing Lewis lung carcinoma.